Federated Hermes, Inc. Aridis Pharmaceuticals, Inc. Transaction History

Federated Hermes, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$5.54 - $8.1 $2,614 - $3,823	-472 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$6.07 - $8.01 $2,160 - $2,851	356 Added 306.9%	472 $3,000
Q3 2020 Nov 12, 2020	BUY	$6.33 - $7.75 $734 - $899	116 New	116 $1,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.